Disease · MONDO_0043919
radiation pneumonitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. radiation pneumonitis. Diseases, record MONDO_0043919. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0043919
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs12
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PENTOXIFYLLINE | CHEMBL628 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ADEBRELIMAB | CHEMBL4297828 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| ENALAPRIL | CHEMBL578 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ENDOSTATIN | CHEMBL4297747 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| HYDROCORTISONE | CHEMBL389621 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| NINTEDANIB | CHEMBL502835 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PREDNISOLONE | CHEMBL131 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
1 to 10 of 12
See all 12 drugsTargets37
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 5 | Glucocorticoid receptor agonist | Phase 2 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 2 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| ACE | Angiotensin-converting enzyme | 1 | Angiotensin-converting enzyme inhibitor | Phase 2 | https://conductscience.org/library/genes/1636 | Drugs and targets |
| ADORA2A | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/135 | Drugs and targets |
| ADORA2B | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/136 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 1 | Programmed cell death 1 ligand 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| FGFR1 | Fibroblast growth factor receptor | 1 | Fibroblast growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2260 | Drugs and targets |
| FGFR2 | Fibroblast growth factor receptor | 1 | Fibroblast growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2263 | Drugs and targets |
| FGFR3 | Fibroblast growth factor receptor | 1 | Fibroblast growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2261 | Drugs and targets |
| FGFR4 | Fibroblast growth factor receptor | 1 | Fibroblast growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2264 | Drugs and targets |
1 to 10 of 37
See all 37 targetsTrials6
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01754909 | Mitigation of Radiation Pneumonitis and Fibrosis | Phase 2 | 50 | 2019-10-01 | Lung Cancer, Radiation Pneumonitis | ENALAPRIL | Its record names the disease | ClinicalTrials.gov |
| NCT02496585 | Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis | Phase 2 | 34 | 2025-04-16 | Lung Cancer, Lung Metastases | NINTEDANIB | Its record names the disease | ClinicalTrials.gov |
| NCT03796364 | Clinical Study of Endostatin in Improving Radiation Pneumonia and Fibrosis | Phase 2 | 126 | Radiation Pneumonitis, Endostatin | ENDOSTATIN | Its record names the disease | ClinicalTrials.gov | |
| NCT06700421 | Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis | Phase 2 | 32 | Unresectable Locally Advanced Non-small Cell Lung Cancer | ADEBRELIMAB, RIVOCERANIB | Its record names the disease | ClinicalTrials.gov | |
| NCT03916068 | Acute Post-Radiation Hyperbaric Oxygen (HBO2) for Breast Cancer Patients Who Have Recently Completed Radiation Therapy | Phase 2 | 1 | Breast Cancer | PENTOXIFYLLINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00022204 | Vitamin E and Pentoxifylline in Treating Women With Lymphedema After Radiation Therapy for Breast Cancer | Phase 2 | Breast Cancer, Lymphedema | PENTOXIFYLLINE, VITAMIN E | Open Targets' reading of its record | ClinicalTrials.gov |
Comparisons in its trials7
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Enalapril vs Placebo: Number of Participants With Radiation Pneumonitis | 8 of 20 | 10 of 23 | 43 | NCT01754909 | Trial comparisons |
| Enalapril vs Placebo: Number of Participants With Radiation Fibrosis | 8 of 20 | 4 of 23 | 43 | NCT01754909 | Trial comparisons |
| Enalapril vs Placebo: deaths from any cause | 11 of 20 | 7 of 23 | 43 | NCT01754909 | Trial comparisons |
| Enalapril vs Placebo: serious adverse events | 9 of 20 | 11 of 23 | 43 | NCT01754909 | Trial comparisons |
| Enalapril vs Placebo: Number of Participants With Radiation Pneumonitis by CT Scan | 16 of 20 | 12 of 21 | 41 | NCT01754909 | Trial comparisons |
| Nintedanib + Prednisone vs Placebo + Prednisone: deaths from any cause | 8 of 18 | 3 of 12 | 30 | NCT02496585 | Trial comparisons |
| Nintedanib + Prednisone vs Placebo + Prednisone: serious adverse events | 7 of 18 | 1 of 12 | 30 | NCT02496585 | Trial comparisons |
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0043919
GET https://conductscience.org/api/diseases/v1/MONDO_0043919/targets?page=2